Trump Promotes Medicaid Drug Price Program Ahead of Midterms
President Trump announced all states have joined an initiative to align Medicaid drug prices with those paid by other wealthy nations.
President Trump promoted a federal program aimed at lowering prescription drug costs for Medicaid, declaring that every state had opted into an effort to bring the government health program's medicine prices in line with those paid by peer nations abroad, according to a report by The New York Times.
The announcement carries clear political overtones, arriving ahead of the midterm elections when drug pricing remains a potent issue for voters across party lines. By framing the initiative as a nationwide achievement — with full state participation — the administration sought to underscore its record on healthcare affordability.
Read more SEC Chair Atkins Moves to Scrap Shareholder Proposal Rules →
The program's core mechanism mirrors a broader policy debate that has persisted for years in Washington: whether the United States should benchmark domestic drug prices against those negotiated by other wealthy countries, which typically pay significantly less for the same medications. Applying that logic to Medicaid, which covers tens of millions of low-income Americans, could translate to substantial savings for both states and the federal government.
Full state participation, if accurate, would mark a notable policy milestone, since Medicaid is jointly administered by federal and state governments, and such programs often face resistance from individual states or pharmaceutical industry stakeholders concerned about revenue impacts. The administration did not immediately release detailed figures on projected savings or implementation timelines, per the Times report.
Continue reading at NYT > Business.
